Opioid Use Disorder
Conditions
Brief summary
This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.
Interventions
DEVICERecoveryPad platform
Telehealth platform to enhance motivation and engagement in treatment for OUD
Sponsors
Yale University
National Institute on Drug Abuse (NIDA)
City University of New York, School of Public Health
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Can speak, read and write in English * Provision of signed and dated informed consent form * Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition * Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) * Can provide a working email address OR be willing to create one
Exclusion criteria
* Current use of buprenorphine, methadone, or naltrexone for a substance use disorder * Pregnancy * Known current suicide risk based on participant self-report * On parole or incarcerated at time of enrollment based on participant self-report
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Attendance for MOUD | Up to 30 days | Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 30 days of enrollment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Attendance for MOUD | Up to 90 days | Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 31 to 90 days of enrollment. |
| Engagement with MOUD | Up to 90 days | Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of enrollment. |
| Overdose Events at 30 Days | Up to 30 days | A self-report of the number of subsequent overdose events within 30 days. |
| Overdose Events at 90 Days | Up to 90 days | A self-report of the number of subsequent overdose events within 90 days. |
Countries
United States
Contacts
CONTACTRebekah Heckmann, MD
PRINCIPAL_INVESTIGATORRebekah Heckmann, MD
Yale University
PRINCIPAL_INVESTIGATORNasim Sabounchi, PhD
CUNY Graduate School of Public Health & Health Policy
Outcome results
None listed